{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:08:18Z","timestamp":1790633298549,"version":"4.1.0"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,12,14]],"date-time":"2013-12-14T00:00:00Z","timestamp":1386979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,12,14]],"date-time":"2013-12-14T00:00:00Z","timestamp":1386979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s40265-013-0159-3","type":"journal-article","created":{"date-parts":[[2013,12,13]],"date-time":"2013-12-13T07:40:20Z","timestamp":1386920420000},"page":"99-125","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["Darunavir: A Review of Its Use in the Management of HIV-1 Infection"],"prefix":"10.1007","volume":"74","author":[{"given":"Emma D.","family":"Deeks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,12,14]]},"reference":[{"issue":"5","key":"159_CR1","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/jac\/dkr599","volume":"67","author":"V Le Douce","year":"2012","unstructured":"Le Douce V, Janossy A, Hallay H, et al. Achieving a cure for HIV infection: do we have reasons to be optimistic? J Antimicrob Chemother. 2012;67(5):1063\u201374.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"159_CR2","doi-asserted-by":"publisher","first-page":"912","DOI":"10.4103\/0971-5916.92636","volume":"134","author":"SN Mothi","year":"2011","unstructured":"Mothi SN, Karpagam S, Swamy VH, et al. Paediatric HIV\u2014trends & challenges. Indian J Med Res. 2011;134(6):912\u20139.","journal-title":"Indian J Med Res"},{"issue":"4","key":"159_CR3","doi-asserted-by":"publisher","first-page":"a007161","DOI":"10.1101\/cshperspect.a007161","volume":"2","author":"EJ Arts","year":"2012","unstructured":"Arts EJ, Hazuda DJ. HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med. 2012;2(4):a007161.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"6","key":"159_CR4","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.coviro.2011.10.020","volume":"1","author":"DR Kuritzkes","year":"2011","unstructured":"Kuritzkes DR. Drug resistance in HIV-1. Curr Opin Virol. 2011;1(6):582\u20139.","journal-title":"Curr Opin Virol"},{"key":"159_CR5","unstructured":"Williams I, Churchill D, Anderson J, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med. 2012;13 Suppl 2:1\u201385. Plus an update available at http:\/\/www.bhiva.org\/documents\/Conferences\/Autumn2013\/presentations\/131114\/DuncanChurchill.pdf. Accessed 26 Nov 2013."},{"key":"159_CR6","unstructured":"European AIDS Clinical Society. Guidelines version 7.0. 2013. http:\/\/www.eacsociety.org\/Portals\/0\/Guidelines_Online_131014.pdf. Accessed 18 Nov 2013."},{"key":"159_CR7","unstructured":"US Department of Health and Human Services panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents; 2013. http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adultandadolescentgl.pdf. Accessed 18 Nov 2013. Plus an update available at http:\/\/aidsinfo.nih.gov\/news\/1392\/hhs-panel-on-antiretroviral-guidelines-for-adults-and-adolescents-updates-recommendations-on-preferred-insti-based-regimens-for-art-naive-individuals. Accessed 26 Nov 2013."},{"issue":"4","key":"159_CR8","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1001\/jama.2012.7961","volume":"308","author":"MA Thompson","year":"2012","unstructured":"Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012;308(4):387\u2013402.","journal-title":"JAMA"},{"issue":"10","key":"159_CR9","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/j.1468-1293.2009.00759.x","volume":"10","author":"S Welch","year":"2009","unstructured":"Welch S, Sharland M, Lyall EG, et al. PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. HIV Med. 2009;10(10):591\u2013613.","journal-title":"HIV Med"},{"key":"159_CR10","unstructured":"US Department of Health and Human Services panel on antiretroviral therapy and medical management of HIV-infected children. Guidelines for the use of antiretroviral agents in pediatric HIV infection; 2012. http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/pediatricguidelines.pdf. Accessed 18 Nov 2013."},{"issue":"Suppl 1","key":"159_CR11","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1097\/01.COH.0000410238.80894.81","volume":"6","author":"F Maltez","year":"2011","unstructured":"Maltez F, Doroana M, Branco T, et al. Recent advances in antiretroviral treatment and prevention in HIV-infected patients. Curr Opin HIV AIDS. 2011;6 Suppl 1:S21\u201330.","journal-title":"Curr Opin HIV AIDS"},{"issue":"6","key":"159_CR12","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1097\/COH.0b013e328331b911","volume":"4","author":"JR Arribas","year":"2009","unstructured":"Arribas JR. Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor\/nonnucleoside reverse transcriptase inhibitor\/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine). Curr Opin HIV AIDS. 2009;4(6):507\u201312.","journal-title":"Curr Opin HIV AIDS"},{"key":"159_CR13","unstructured":"Janssen-Cilag International NV. Prezista: EU summary of product characteristics; 2013. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000707\/WC500041756.pdf. Accessed 14 Nov 2013."},{"key":"159_CR14","unstructured":"Janssen Pharmaceuticals Inc. Prezista (darunavir): US prescribing information; 2013. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/021976s033_202895s010lbl.pdf. Accessed 14 Nov 2013."},{"issue":"4","key":"159_CR15","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2165\/00003495-200969040-00007","volume":"69","author":"K McKeage","year":"2009","unstructured":"McKeage K, Perry CM, Keam SJ. Darunavir: a review of its use in the management of HIV infection in adults. Drugs. 2009;69(4):477\u2013503.","journal-title":"Drugs"},{"issue":"18","key":"159_CR16","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.2165\/00003495-200767180-00010","volume":"67","author":"C Fenton","year":"2007","unstructured":"Fenton C, Perry CM. Darunavir: in the treatment of HIV-1 infection. Drugs. 2007;67(18):2791\u2013801.","journal-title":"Drugs"},{"issue":"Suppl 1","key":"159_CR17","first-page":"S59","volume":"39","author":"I Sauzullo","year":"2011","unstructured":"Sauzullo I, Mengoni F, Ermocida A, et al. Pharmacological modulation of apoptosis of PBMC by darunavir and maraviroc [abstract no. PO11]. Infection. 2011;39 Suppl 1:S59.","journal-title":"Infection"},{"key":"159_CR18","doi-asserted-by":"crossref","first-page":"18202","DOI":"10.7448\/IAS.15.6.18202","volume":"15","author":"E Martinez","year":"2012","unstructured":"Martinez E, Gonzalez-Cordon A, Podzamczer D, et al. Metabolic effects of atazanavir\/ritonavir vs darunavir\/ritonavir in combination with tenofovir\/emtricitabine in antiretroviral-naive patients (ATADAR Study) [abstract no. 0423]. J Int AIDS Soc. 2012;15 Suppl 4:18202.","journal-title":"J Int AIDS Soc"},{"key":"159_CR19","doi-asserted-by":"crossref","unstructured":"Kakuda TN, Tomaka F, Van De Casteele T, et al. Generalised additive model analysis of the relationship between darunavir pharmacokinetics and pharmacodynamics following once-daily darunavir\/ritonavir 800\/100\u00a0mg treatment in the phase III trials, ARTEMIS and ODIN [abstract no. P072]. 11th International Congress on Drug Therapy in HIV Infection; 11\u201315 Nov 2012; Glasgow.","DOI":"10.7448\/IAS.15.6.18338"},{"key":"159_CR20","unstructured":"Violari A, Bologna R, Kumarasamy N, et al. Safety and efficacy of darunavir\/ritonavir in treatment-experienced pediatric patients aged 3 to\u00a0<\u00a06\u00a0years: week 48 analysis of the ARIEL trial [abstract no. MOAB0102]. 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; 30 Jun\u20133 Jul 2013; Kuala Lumpur."},{"key":"159_CR21","unstructured":"Violari A, Bologna R, Kimutai R, et al. ARIEL: 24-week safety and efficacy of darunavir\/ritonavir in treatment-experienced pediatric patients aged 3 to <6\u00a0years [abstract no. 713 plus poster]. 18th Conference on Retroviruses and Opportunistic Infections; 27 Feb\u20132 Mar 2011; Boston (MA)."},{"key":"159_CR22","unstructured":"US FDA Center for Drug Evaluation and Research. Application number 21-976: microbiology review; 2005. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2006\/021976s000_Sprycel_MicroR.pdf. Accessed 18 Nov 2013."},{"issue":"39","key":"159_CR23","doi-asserted-by":"publisher","first-page":"28709","DOI":"10.1074\/jbc.M703938200","volume":"282","author":"Y Koh","year":"2007","unstructured":"Koh Y, Matsumi S, Das D, et al. Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. J Biol Chem. 2007;282(39):28709\u201320.","journal-title":"J Biol Chem"},{"issue":"21","key":"159_CR24","doi-asserted-by":"publisher","first-page":"12012","DOI":"10.1128\/JVI.78.21.12012-12021.2004","volume":"78","author":"NM King","year":"2004","unstructured":"King NM, Prabu-Jeyabalan M, Nalivaika EA, et al. Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J Virol. 2004;78(21):12012\u201321.","journal-title":"J Virol"},{"issue":"1","key":"159_CR25","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1021\/ci7001318","volume":"48","author":"K Nivesanond","year":"2008","unstructured":"Nivesanond K, Peeters A, Lamoen D, et al. Conformational analysis of TMC114, a novel HIV-1 protease inhibitor. J Chem Inf Model. 2008;48(1):99\u2013108.","journal-title":"J Chem Inf Model"},{"issue":"24","key":"159_CR26","doi-asserted-by":"publisher","first-page":"13845","DOI":"10.1128\/JVI.01184-07","volume":"81","author":"I Dierynck","year":"2007","unstructured":"Dierynck I, De Wit M, Gustin E, et al. Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier. J Virol. 2007;81(24):13845\u201351.","journal-title":"J Virol"},{"issue":"19","key":"159_CR27","doi-asserted-by":"publisher","first-page":"10079","DOI":"10.1128\/JVI.05121-11","volume":"85","author":"Y Koh","year":"2011","unstructured":"Koh Y, Aoki M, Danish ML, et al. Loss of protease dimerization inhibition activity of darunavir is associated with the acquisition of resistance to darunavir by HIV-1. J Virol. 2011;85(19):10079\u201389.","journal-title":"J Virol"},{"issue":"10","key":"159_CR28","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1128\/AAC.47.10.3123-3129.2003","volume":"47","author":"Y Koh","year":"2003","unstructured":"Koh Y, Nakata H, Maeda K, et al. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob Agents Chemother. 2003;47(10):3123\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"159_CR29","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1128\/AAC.49.6.2314-2321.2005","volume":"49","author":"S De Meyer","year":"2005","unstructured":"De Meyer S, Azijn H, Surleraux D, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother. 2005;49(6):2314\u201321.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"159_CR30","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.3851\/IMP1697","volume":"15","author":"I Dierynck","year":"2010","unstructured":"Dierynck I, De Meyer S, Lathouwers E, et al. In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients. Antivir Ther. 2010;15(8):1161\u20139.","journal-title":"Antivir Ther"},{"issue":"1","key":"159_CR31","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1468-1293.2012.01060.x","volume":"14","author":"C Orkin","year":"2013","unstructured":"Orkin C, Dejesus E, Khanlou H, et al. Final 192-week efficacy and safety of once-daily darunavir\/ritonavir compared with lopinavir\/ritonavir in HIV-1-infected treatment-naive patients in the ARTEMIS trial. HIV Med. 2013;14(1):49\u201359.","journal-title":"HIV Med"},{"issue":"7","key":"159_CR32","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1097\/QAD.0b013e328345ee95","volume":"25","author":"P Cahn","year":"2011","unstructured":"Cahn P, Fourie J, Grinsztejn B, et al. Week 48 analysis of once-daily vs. twice-daily darunavir\/ritonavir in treatment-experienced HIV-1-infected patients. AIDS. 2011;25(7):929\u201339.","journal-title":"AIDS"},{"issue":"3","key":"159_CR33","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3851\/IMP2569","volume":"18","author":"E Lathouwers","year":"2013","unstructured":"Lathouwers E, De La Rosa G, Van de Casteele T, et al. Virological analysis of once-daily and twice-daily darunavir\/ritonavir in the ODIN trial of treatment-experienced patients. Antivir Ther. 2013;18(3):289\u2013300.","journal-title":"Antivir Ther"},{"issue":"3","key":"159_CR34","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1089\/aid.2007.0173","volume":"24","author":"S De Meyer","year":"2008","unstructured":"De Meyer S, Vangeneugden T, van Baelen B, et al. Resistance profile of darunavir: combined 24-week results from the POWER trials. AIDS Res Hum Retroviruses. 2008;24(3):379\u201388.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"2","key":"159_CR35","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2174\/157016212799937218","volume":"10","author":"D Banhegyi","year":"2012","unstructured":"Banhegyi D, Katlama C, da Cunha CA, et al. Week 96 efficacy, virology and safety of darunavir\/r versus lopinavir\/r in treatment-experienced patients in TITAN. Curr HIV Res. 2012;10(2):171\u201381.","journal-title":"Curr HIV Res"},{"issue":"15","key":"159_CR36","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1097\/QAD.0b013e328330abaa","volume":"23","author":"S Blanche","year":"2009","unstructured":"Blanche S, Bologna R, Cahn P, et al. Pharmacokinetics, safety and efficacy of darunavir\/ritonavir in treatment-experienced children and adolescents. AIDS. 2009;23(15):2005\u201313.","journal-title":"AIDS"},{"issue":"7","key":"159_CR37","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1128\/AAC.00160-10","volume":"54","author":"E Poveda","year":"2010","unstructured":"Poveda E, Anta L, Blanco JL, et al. Drug resistance mutations in HIV-infected patients in the Spanish drug resistance database failing tipranavir and darunavir therapy. Antimicrob Agents Chemother. 2010;54(7):3018\u201320.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"159_CR38","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1093\/jac\/dkn544","volume":"63","author":"D Descamps","year":"2009","unstructured":"Descamps D, Lambert-Niclot S, Marcelin A-G, et al. Mutations associated with virological response to darunavir\/ritonavir in HIV-1-infected protease inhibitor-experienced patients. J Antimicrob Chemother. 2009;63(3):585\u201392.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"159_CR39","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/j.1472-8206.2011.00949.x","volume":"26","author":"E Dailly","year":"2012","unstructured":"Dailly E, Rodallec A, Allavena C, et al. Virological response to darunavir in patients infected with HIV is linked to darunavir resistance-associated mutations corrected by the count of mutations with positive impact and is not associated with pharmacological and combined virological\/pharmacological parameters. Fundam Clin Pharmacol. 2012;26(4):538\u201342.","journal-title":"Fundam Clin Pharmacol"},{"issue":"11","key":"159_CR40","doi-asserted-by":"publisher","first-page":"3928","DOI":"10.1128\/AAC.00520-08","volume":"52","author":"J Molto","year":"2008","unstructured":"Molto J, Santos JR, Perez-Alvarez N, et al. Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients. Antimicrob Agents Chemother. 2008;52(11):3928\u201332.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"159_CR41","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/135965350801300214","volume":"13","author":"I Pellegrin","year":"2008","unstructured":"Pellegrin I, Wittkop L, Joubert LM, et al. Virological response to darunavir\/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study). Antivir Ther. 2008;13(2):271\u20139.","journal-title":"Antivir Ther"},{"issue":"3","key":"159_CR42","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.jcv.2009.12.022","volume":"47","author":"C Delaugerre","year":"2010","unstructured":"Delaugerre C, Buyck JF, Peytavin G, et al. Factors predictive of successful darunavir\/ritonavir-based therapy in highly antiretroviral-experienced HIV-1-infected patients (the DARWEST study). J Clin Virol. 2010;47(3):248\u201352.","journal-title":"J Clin Virol"},{"issue":"5","key":"159_CR43","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1097\/QAI.0b013e31824bb720","volume":"59","author":"C Fagard","year":"2012","unstructured":"Fagard C, Colin C, Charpentier C, et al. Long-term efficacy and safety of raltegravir, etravirine, and darunavir\/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial. J Acquir Immune Defic Syndr. 2012;59(5):489\u201393.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9581","key":"159_CR44","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0140-6736(07)61049-6","volume":"370","author":"JV Madruga","year":"2007","unstructured":"Madruga JV, Berger D, McMurchie M, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48\u00a0weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet. 2007;370(9581):49\u201358.","journal-title":"Lancet"},{"issue":"9568","key":"159_CR45","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/S0140-6736(07)60497-8","volume":"369","author":"B Clotet","year":"2007","unstructured":"Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007;369(9568):1169\u201378.","journal-title":"Lancet"},{"issue":"12","key":"159_CR46","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1097\/QAD.0b013e32830285fb","volume":"22","author":"R Ortiz","year":"2008","unstructured":"Ortiz R, Dejesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir\/ritonavir versus lopinavir\/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS. 2008;22(12):1389\u201397.","journal-title":"AIDS"},{"issue":"13","key":"159_CR47","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1097\/QAD.0b013e32832d7350","volume":"23","author":"AM Mills","year":"2009","unstructured":"Mills AM, Nelson M, Jayaweera D, et al. Once-daily darunavir\/ritonavir vs. lopinavir\/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS. 2009;23(13):1679\u201388.","journal-title":"AIDS"},{"issue":"17","key":"159_CR48","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1097\/QAD.0b013e32834bbaa9","volume":"25","author":"B Taiwo","year":"2011","unstructured":"Taiwo B, Zheng L, Gallien S, et al. Efficacy of a nucleoside-sparing regimen of darunavir\/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS. 2011;25(17):2113\u201322.","journal-title":"AIDS"},{"key":"159_CR49","doi-asserted-by":"crossref","unstructured":"Pozniak A, Arasteh K, Molina JM, et al. POWER 3 analysis: 144-week efficacy and safety results for darunavir\/ritonavir 600\/100\u00a0mg bid in treatment-experienced HIV patients [poster]. 9th International Conference on Drug Therapy in HIV Infection; 9\u201313 Nov 2008; Glasgow.","DOI":"10.1186\/1758-2652-11-S1-P24"},{"issue":"6","key":"159_CR50","doi-asserted-by":"publisher","first-page":"859","DOI":"10.3851\/IMP1301","volume":"14","author":"K Arasteh","year":"2009","unstructured":"Arasteh K, Yeni P, Pozniak A, et al. Efficacy and safety of darunavir\/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96. Antivir Ther. 2009;14(6):859\u201364.","journal-title":"Antivir Ther"},{"issue":"10","key":"159_CR51","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1089\/aid.2011.0327","volume":"28","author":"JA Aberg","year":"2012","unstructured":"Aberg JA, Tebas P, Overton ET, et al. Metabolic effects of darunavir\/ritonavir versus atazanavir\/ritonavir in treatment-naive, HIV type 1-infected subjects over 48\u00a0weeks. AIDS Res Hum Retroviruses. 2012;28(10):1184\u201395.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"6","key":"159_CR52","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1089\/apc.2010.0386","volume":"25","author":"JS Currier","year":"2011","unstructured":"Currier JS, Martorell C, Osiyemi O, et al. Effects of darunavir\/ritonavir-based therapy on metabolic and anthropometric parameters in women and men over 48\u00a0weeks. AIDS Patient Care STDS. 2011;25(6):333\u201340.","journal-title":"AIDS Patient Care STDS"},{"issue":"2","key":"159_CR53","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2165\/11204530-000000000-00000","volume":"12","author":"K McKeage","year":"2010","unstructured":"McKeage K, Scott LJ. Darunavir: in treatment-experienced pediatric patients with HIV-1 infection. Paediatr Drugs. 2010;12(2):123\u201331.","journal-title":"Paediatr Drugs"},{"key":"159_CR54","doi-asserted-by":"crossref","unstructured":"Poupard M, Boussairi A, Krause J, et al. Darunavir plasma level in HIV overweight patients [abstract no. P78]. J Int AIDS Soc. 2012;15 Suppl 4(6):18359. Plus poster presented at the 11th International Congress on Drug Therapy in HIV Infection; 11\u201315 Nov 2012; Glasgow.","DOI":"10.7448\/IAS.15.6.18359"},{"key":"159_CR55","unstructured":"Colbers A, Molto J, Ivanovic J, et al. A comparison of the pharmacokinetics of darunavir, atazanavir, and ritonavir during pregnancy and post-partum [abstract no. 1013 plus poster]. 19th Conference on Retroviruses and Opportunistic Infections; 5\u20138 Mar 2012; Seattle (WA)."},{"key":"159_CR56","first-page":"96","volume":"8","author":"EV Capparelli","year":"2011","unstructured":"Capparelli EV, Best BM, Stek A, et al. Pharmacokinetics of darunavir once or twice daily during and after pregnancy [abstract no. P_72]. Rev Antiviral Ther Infect Dis. 2011;8:96\u20137.","journal-title":"Rev Antiviral Ther Infect Dis"},{"key":"159_CR57","unstructured":"Courbon E, Matheron S, Mandelbrot L, et al. Safety, efficacy and pharmacokinetic of darunavir\/ritonavir-containing regimen in pregnant HIV+\u00a0women [abstract no. 1011]. 19th Conference on Retroviruses and Opportunistic Infections; 5\u20138 Mar 2012; Seattle (WA)."},{"issue":"Suppl 1","key":"159_CR58","first-page":"S70","volume":"39","author":"J Ivanovic","year":"2011","unstructured":"Ivanovic J, Bellagamba R, Tempestilli M, et al. Successful use of a darunavir\/ritonavir in five pregnant women: pharmacokinetics, efficacy and safety [abstract no. PO42]. Infection. 2011;39 Suppl 1:S70.","journal-title":"Infection"},{"issue":"Suppl 2","key":"159_CR59","first-page":"35","volume":"14","author":"MG Rizzo","year":"2013","unstructured":"Rizzo MG. Safety of boosted-darunavir as part of the HAART prophylaxis regimen during pregnancy [abstract no. P77]. HIV Med. 2013;14 Suppl 2:35.","journal-title":"HIV Med"},{"issue":"4","key":"159_CR60","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1177\/0091270006298603","volume":"47","author":"V Sekar","year":"2007","unstructured":"Sekar V, Kestens D, Spinosa-Guzman S, et al. The effect of different meal types on the pharmacokinetics of darunavir (TMC114)\/ritonavir in HIV-negative healthy volunteers. J Clin Pharmacol. 2007;47(4):479\u201384.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"159_CR61","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1128\/AAC.00889-10","volume":"55","author":"K Patterson","year":"2011","unstructured":"Patterson K, Jennings S, Falcon R, et al. Darunavir, ritonavir, and etravirine pharmacokinetics in the cervicovaginal fluid and blood plasma of HIV-infected women. Antimicrob Agents Chemother. 2011;55(3):1120\u20132.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"159_CR62","doi-asserted-by":"publisher","first-page":"4910","DOI":"10.1128\/AAC.00725-10","volume":"54","author":"S Lambert-Niclot","year":"2010","unstructured":"Lambert-Niclot S, Peytavin G, Duvivier C, et al. Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavir-ritonavir at 600\/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapy. Antimicrob Agents Chemother. 2010;54(11):4910\u20133.","journal-title":"Antimicrob Agents Chemother"},{"issue":"16","key":"159_CR63","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1097\/QAD.0b013e32833ead18","volume":"24","author":"S Taylor","year":"2010","unstructured":"Taylor S, Jayasuriya AN, Berry A, et al. Darunavir concentrations exceed the protein-corrected EC50 for wild-type HIV in the semen of HIV-1-infected men. AIDS. 2010;24(16):2583\u20137.","journal-title":"AIDS"},{"issue":"12","key":"159_CR64","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1097\/QAD.0b013e3283553619","volume":"26","author":"A Calcagno","year":"2012","unstructured":"Calcagno A, Yilmaz A, Cusato J, et al. Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics. AIDS. 2012;26(12):1529\u201333.","journal-title":"AIDS"},{"issue":"3","key":"159_CR65","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1093\/jac\/dks441","volume":"68","author":"D Croteau","year":"2013","unstructured":"Croteau D, Rossi SS, Best BM, et al. Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentration. J Antimicrob Chemother. 2013;68(3):684\u20139.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"159_CR66","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1089\/aid.2008.0216","volume":"25","author":"A Yilmaz","year":"2009","unstructured":"Yilmaz A, Izadkhashti A, Price RW, et al. Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals. AIDS Res Hum Retroviruses. 2009;25(4):457\u201361.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"5","key":"159_CR67","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2165\/11530690-000000000-00000","volume":"49","author":"V Sekar","year":"2010","unstructured":"Sekar V, Spinosa-Guzman S, De Paepe E, et al. Pharmacokinetics of multiple-dose darunavir in combination with low-dose ritonavir in individuals with mild-to-moderate hepatic impairment. Clin Pharmacokinet. 2010;49(5):343\u201350.","journal-title":"Clin Pharmacokinet"},{"key":"159_CR68","doi-asserted-by":"publisher","unstructured":"Kakuda T, Sekar V, Vis P, et al. Pharmacokinetics and pharmacodynamics of darunavir and etravirine in HIV-1-infected, treatment-experienced patients in the Gender, Race, and Clinical Experience (GRACE) trial. AIDS Res Treat. 2012. doi:10.1155\/2012\/186987.","DOI":"10.1155\/2012\/186987"},{"issue":"4","key":"159_CR69","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1310\/hct0804-213","volume":"8","author":"A Rachlis","year":"2007","unstructured":"Rachlis A, Clotet B, Baxter J, et al. Safety, tolerability, and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced, hepatitis B or C co-infected patients in POWER 1 and 3. HIV Clin Trials. 2007;8(4):213\u201320.","journal-title":"HIV Clin Trials"},{"key":"159_CR70","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12047","author":"C Zorrilla","year":"2013","unstructured":"Zorrilla C, Wright R, Osiyemi O, et al. Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir\/ritonavir 600\/100\u00a0mg administered twice daily. HIV Med. 2013. doi:10.1111\/hiv.12047.","journal-title":"HIV Med"},{"issue":"9","key":"159_CR71","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1086\/630210","volume":"49","author":"Y Yazdanpanah","year":"2009","unstructured":"Yazdanpanah Y, Fagard C, Descamps D, et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir\/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis. 2009;49(9):1441\u20139.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"159_CR72","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/QAI.0b013e3181359cfb","volume":"46","author":"JM Molina","year":"2007","unstructured":"Molina JM, Cohen C, Katlama C, et al. Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3. J Acquir Immune Defic Syndr. 2007;46(1):24\u201331.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"159_CR73","doi-asserted-by":"publisher","first-page":"349","DOI":"10.7326\/0003-4819-153-6-201009210-00002","volume":"153","author":"J Currier","year":"2010","unstructured":"Currier J, Averitt Bridge D, Hagins D, et al. Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. Ann Intern Med. 2010;153(6):349\u201357.","journal-title":"Ann Intern Med"},{"key":"159_CR74","doi-asserted-by":"crossref","unstructured":"Bedimo R, Drechsler H, Cutrell J, et al. RADAR study: week 48 safety and efficacy of raltegravir combined with boosted darunavir compared to tenofovir\/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Impact on bone health [abstract no. WEPE512 plus poster]. 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; 30 Jun\u20133 Jul 2013; Kuala Lumpur.","DOI":"10.1371\/journal.pone.0106221"},{"key":"159_CR75","unstructured":"Lewin J. DIONE - 24\u00a0week efficacy, safety, tolerability and pharmacokinetics of DRV\/r QD in treatment-naive adolescents, 12 to\u00a0<\u00a018\u00a0years [conference report on the 6th International AIDS Society Conference on HIV Pathogenesis Treatment and Prevention]; 2011. http:\/\/www.natap.org\/2011\/IAS\/IAS_40.htm. Accessed 24 Sep 2013."},{"issue":"4","key":"159_CR76","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1097\/QAD.0b013e328013d9d7","volume":"21","author":"C Katlama","year":"2007","unstructured":"Katlama C, Esposito R, Gatell JM, et al. Efficacy and safety of TMC114\/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS. 2007;21(4):395\u2013402.","journal-title":"AIDS"},{"issue":"6","key":"159_CR77","doi-asserted-by":"publisher","first-page":"F11","DOI":"10.1097\/QAD.0b013e3280b07b47","volume":"21","author":"R Haubrich","year":"2007","unstructured":"Haubrich R, Berger D, Chiliade P, et al. Week 24 efficacy and safety of TMC114\/ritonavir in treatment-experienced HIV patients. AIDS. 2007;21(6):F11\u20138.","journal-title":"AIDS"},{"issue":"Suppl 1","key":"159_CR78","first-page":"S63","volume":"39","author":"A Lazzarin","year":"2011","unstructured":"Lazzarin A, Mazzotta F, Mezzaroma I, et al. Health-related quality of life (HRQOL) assessment with once- and twice-daily darunavir\/ritonavir (DRV\/R) in the ODIN trial [abstract no. PO 26]. Infection. 2011;39 Suppl 1:S63\u20134.","journal-title":"Infection"},{"key":"159_CR79","doi-asserted-by":"crossref","unstructured":"Katlama C, Bellos N, Grinsztejn B, et al. POWER 1 and 2: combined final 144-week efficacy and safety results for darunavir\/ritonavir 600\/100\u00a0mg bid in treatment-experienced HIV patients [poster]. 9th International Congress on Drug Therapy in HIV Infection; 9\u201313 Nov 2008; Glasgow.","DOI":"10.1186\/1758-2652-11-S1-P21"},{"issue":"6","key":"159_CR80","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1310\/hct1206-313","volume":"12","author":"J Fourie","year":"2011","unstructured":"Fourie J, Flamm J, Rodriguez-French A, et al. Effect of baseline characteristics on the efficacy and safety of once-daily darunavir\/ ritonavir in HIV-1-infected, treatment-naive ARTEMIS patients at week 96. HIV Clin Trials. 2011;12(6):313\u201322.","journal-title":"HIV Clin Trials"},{"issue":"7\u20138","key":"159_CR81","first-page":"366","volume":"104","author":"KY Smith","year":"2012","unstructured":"Smith KY, Garcia F, Kumar P, et al. Assessing darunavir\/ritonavir-based therapy in a racially diverse population: 48-week outcomes from GRACE. J Natl Med Assoc. 2012;104(7\u20138):366\u201376.","journal-title":"J Natl Med Assoc"},{"key":"159_CR82","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12024","author":"M Sension","year":"2013","unstructured":"Sension M, Cahn P, Domingo P, et al. Subgroup analysis of virological response rates with once- and twice-daily darunavir\/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial. HIV Med. 2013. doi:10.1111\/hiv.12024.","journal-title":"HIV Med"},{"key":"159_CR83","doi-asserted-by":"publisher","DOI":"10.1258\/ijsa.2012.012120","author":"E Arathoon","year":"2013","unstructured":"Arathoon E, Schneider S, Baraldi E, et al. Effects of once-daily darunavir\/ritonavir versus lopinavir\/ritonavir on metabolic parameters in treatment-naive HIV-1-infected patients at week 96: ARTEMIS. Int J STD AIDS. 2013. doi:10.1258\/ijsa.2012.012120.","journal-title":"Int J STD AIDS"},{"issue":"5","key":"159_CR84","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s40273-013-0048-3","volume":"31","author":"KN Simpson","year":"2013","unstructured":"Simpson KN, Pei PP, Moller J, et al. Lopinavir\/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States. Pharmacoeconomics. 2013;31(5):427\u201344.","journal-title":"Pharmacoeconomics"},{"issue":"7","key":"159_CR85","doi-asserted-by":"publisher","first-page":"A280","DOI":"10.1016\/j.jval.2011.08.268","volume":"14","author":"PO Thuresson","year":"2011","unstructured":"Thuresson PO, Verheggen B, Heeg B, et al. Cost-effectiveness of atazanavir\/r compared to darunavir\/r in Germany [abstract no. PIN82]. Value Health. 2011;14(7):A280.","journal-title":"Value Health"},{"issue":"7","key":"159_CR86","doi-asserted-by":"publisher","first-page":"A393","DOI":"10.1016\/j.jval.2012.08.1115","volume":"15","author":"M Santos","year":"2012","unstructured":"Santos M, Stenut S, Ferraq W, et al. Cost-effectiveness analysis of darunavir versus atazanavir, each in combination with emtricitabine and tenofovir, for the management of naive anti-retroviral HIV infected patients, under the Belgian social security perspective [abstract no. PIN48]. Value Health. 2012;15(7):A393\u20134.","journal-title":"Value Health"},{"issue":"3","key":"159_CR87","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1310\/hct1103-133","volume":"11","author":"AJ Brogan","year":"2010","unstructured":"Brogan AJ, Mrus J, Hill A, et al. Comparative cost-efficacy analysis of darunavir\/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States. HIV Clin Trials. 2010;11(3):133\u201344.","journal-title":"HIV Clin Trials"},{"issue":"Suppl 1","key":"159_CR88","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2165\/11587490-000000000-00000","volume":"28","author":"A Brogan","year":"2010","unstructured":"Brogan A, Mauskopf J, Talbird SE, et al. US cost effectiveness of darunavir\/ritonavir 600\/100\u00a0mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial. Pharmacoeconomics. 2010;28 Suppl 1:129\u201346.","journal-title":"Pharmacoeconomics"},{"issue":"Suppl 1","key":"159_CR89","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2165\/11587500-000000000-00000","volume":"28","author":"K Moeremans","year":"2010","unstructured":"Moeremans K, Hemmett L, Hjelmgren J, et al. Cost effectiveness of darunavir\/ritonavir 600\/100\u00a0mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK. Pharmacoeconomics. 2010;28 Suppl 1:147\u201367.","journal-title":"Pharmacoeconomics"},{"issue":"Suppl 1","key":"159_CR90","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2165\/11587470-000000000-00000","volume":"28","author":"J Mauskopf","year":"2010","unstructured":"Mauskopf J, Brogan A, Martin S, et al. Cost effectiveness of darunavir\/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA. Pharmacoeconomics. 2010;28 Suppl 1:83\u2013105.","journal-title":"Pharmacoeconomics"},{"issue":"Suppl 1","key":"159_CR91","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2165\/11587480-000000000-00000","volume":"28","author":"K Moeremans","year":"2010","unstructured":"Moeremans K, Annemans L, Lothgren M, et al. Cost effectiveness of darunavir\/ritonavir 600\/100\u00a0mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK. Pharmacoeconomics. 2010;28 Suppl 1:107\u201328.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"159_CR92","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1089\/apc.2007.0099","volume":"22","author":"R Kim","year":"2008","unstructured":"Kim R, Baxter JD. Protease inhibitor resistance update: where are we now? AIDS Patient Care STDS. 2008;22(4):267\u201377.","journal-title":"AIDS Patient Care STDS"},{"issue":"1","key":"159_CR93","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.antiviral.2009.10.003","volume":"85","author":"AM Wensing","year":"2010","unstructured":"Wensing AM, van Maarseveen NM, Nijhuis M. Fifteen years of HIV protease inhibitors: raising the barrier to resistance. Antiviral Res. 2010;85(1):59\u201374.","journal-title":"Antiviral Res"},{"key":"159_CR94","unstructured":"US National Institutes of Health. ClinicalTrials.gov; 2013. http:\/\/www.clinicaltrials.gov. Accessed 19 Nov 2013."},{"issue":"9636","key":"159_CR95","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/S0140-6736(08)61139-3","volume":"372","author":"J Ananworanich","year":"2008","unstructured":"Ananworanich J, Puthanakit T, Saphonn V, et al. Lessons from a multicentre paediatric HIV trial. Lancet. 2008;372(9636):356\u20137.","journal-title":"Lancet"},{"issue":"10","key":"159_CR96","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.2165\/00003495-200868100-00006","volume":"68","author":"JS Orman","year":"2008","unstructured":"Orman JS, Perry CM. Tipranavir: a review of its use in the management of HIV infection. Drugs. 2008;68(10):1435\u201363.","journal-title":"Drugs"},{"key":"159_CR97","unstructured":"Boehringer Ingelheim International GmbH. Aptivus (tipranavir): US prescribing information; 2012. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021814s013,022292s006lbl.pdf. Accessed 18 Nov 2013."},{"key":"159_CR98","unstructured":"Boehringer Ingelheim International GmbH. Aptivus: EU summary of product characteristics; 2013. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000631\/WC500025936.pdf. Accessed 18 Nov 2013."},{"issue":"6","key":"159_CR99","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1177\/1545109710382041","volume":"9","author":"T Antoniou","year":"2010","unstructured":"Antoniou T, Raboud JM, Diong C, et al. Virologic and immunologic effectiveness of tipranavir\/ritonavir (TPV\/r)- versus darunavir\/ritonavir (DRV\/r)-based regimens in clinical practice. J Int Assoc Physicians AIDS Care (Chic). 2010;9(6):382\u20139.","journal-title":"J Int Assoc Physicians AIDS Care (Chic)"},{"issue":"4","key":"159_CR100","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2165\/11596340-000000000-00000","volume":"11","author":"MM Elgadi","year":"2011","unstructured":"Elgadi MM, Piliero PJ. Boosted tipranavir versus darunavir in treatment-experienced patients: observational data from the randomized POTENT trial. Drugs R D. 2011;11(4):295\u2013302.","journal-title":"Drugs R D"},{"key":"159_CR101","unstructured":"World Health Organization. HIV drug resistance fact sheet; 2011. http:\/\/www.who.int\/hiv\/facts\/drug_resistance\/en\/. Accessed 27 Sep 2013."},{"issue":"4","key":"159_CR102","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1093\/jac\/dkm276","volume":"60","author":"E Poveda","year":"2007","unstructured":"Poveda E, de Mendoza C, Martin-Carbonero L, et al. Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors. J Antimicrob Chemother. 2007;60(4):885\u20138.","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"159_CR103","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1086\/521624","volume":"196","author":"Y Mitsuya","year":"2007","unstructured":"Mitsuya Y, Liu TF, Rhee SY, et al. Prevalence of darunavir resistance-associated mutations: patterns of occurrence and association with past treatment. J Infect Dis. 2007;196(8):1177\u20139.","journal-title":"J Infect Dis"},{"issue":"Suppl 4","key":"159_CR104","doi-asserted-by":"publisher","first-page":"P132","DOI":"10.1186\/1758-2652-13-S4-P132","volume":"13","author":"G De La Rosa","year":"2010","unstructured":"De La Rosa G, Pattery T, Picchio G, et al. Changing prevalence of darunavir resistance associated mutations (DRV RAMs) in clinical samples received for routine resistance testing: 2003\u20132009 [abstract]. J Int AIDS Soc. 2010;13 Suppl 4:P132.","journal-title":"J Int AIDS Soc"},{"key":"159_CR105","doi-asserted-by":"crossref","unstructured":"Marcelin AG, Charpentier C, Wirden M, et al. Darunavir resistance spectrum in darunavir-naive patients harboring virological failure to antiretroviral therapy [abstract]. 10th International Congress on Drug Therapy in HIV Infection; 7\u201311 Nov 2010; Glasgow.","DOI":"10.1186\/1758-2652-13-S4-P133"},{"issue":"6","key":"159_CR106","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1093\/jac\/dkq130","volume":"65","author":"S Naggie","year":"2010","unstructured":"Naggie S, Hicks C. Protease inhibitor-based antiretroviral therapy in treatment-naive HIV-1-infected patients: the evidence behind the options. J Antimicrob Chemother. 2010;65(6):1094\u20139.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"159_CR107","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/QAD.0b013e3283348944","volume":"24","author":"JR Arribas","year":"2010","unstructured":"Arribas JR, Horban A, Gerstoft J, et al. The MONET trial: darunavir\/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies\/ml. AIDS. 2010;24(2):223\u201330.","journal-title":"AIDS"},{"issue":"15","key":"159_CR108","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1097\/QAD.0b013e32833dec20","volume":"24","author":"C Katlama","year":"2010","unstructured":"Katlama C, Valantin MA, Algarte-Genin M, et al. Efficacy of darunavir\/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS. 2010;24(15):2365\u201374.","journal-title":"AIDS"},{"key":"159_CR109","unstructured":"Santos JR, Molto J, Llibre JM, et al. Randomised study to evaluate lopinavir\/ritonavir vs. darunavir\/ritonavir monotherapies as simplification of triple therapy regimens [abstract no. WEPE514 plus poster]. 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; 30 Jun\u20133 Jul 2013; Kuala Lumpur."},{"issue":"5","key":"159_CR110","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1310\/hct1305-256","volume":"13","author":"ET Overton","year":"2012","unstructured":"Overton ET, Arathoon E, Baraldi E, et al. Effect of darunavir on lipid profile in HIV-infected patients. HIV Clin Trials. 2012;13(5):256\u201370.","journal-title":"HIV Clin Trials"},{"issue":"6","key":"159_CR111","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1111\/j.1365-2796.2010.02301.x","volume":"268","author":"F Josephson","year":"2010","unstructured":"Josephson F. Drug-drug interactions in the treatment of HIV infection: focus on pharmacokinetic enhancement through CYP3A inhibition. J Intern Med. 2010;268(6):530\u20139.","journal-title":"J Intern Med"},{"key":"159_CR112","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1237","author":"BM Shah","year":"2013","unstructured":"Shah BM, Schafer JJ, Priano J, et al. Cobicistat: a new boost for the treatment of human immunodeficiency virus infection. Pharmacotherapy. 2013. doi:10.1002\/phar.1237.","journal-title":"Pharmacotherapy"},{"key":"159_CR113","unstructured":"Gilead Sciences Intl Ltd. Tybost 150\u00a0mg film-coated tablets: EU summary of product characteristics; 2013. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002572\/WC500153014.pdf. Accessed 18 Nov 2013."},{"key":"159_CR114","unstructured":"AIDS.GOV. The global HIV\/AIDS crisis today; 2013. http:\/\/aids.gov\/hiv-aids-basics\/hiv-aids-101\/global-statistics\/. Accessed 27 Sep 2013."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0159-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-013-0159-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0159-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0159-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T12:33:23Z","timestamp":1659098003000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-013-0159-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,14]]},"references-count":114,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["159"],"URL":"https:\/\/doi.org\/10.1007\/s40265-013-0159-3","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,14]]},"assertion":[{"value":"14 December 2013","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}